Treatment strategies for patients with severe aplastic anemia

被引:24
作者
Bacigalupo, A. [1 ]
机构
[1] Osped San Martino Genova, Dept Hematol, Genoa, Italy
关键词
hematopoietic SCT; aplastic anemia; bone marrow aplasia;
D O I
10.1038/bmt.2008.113
中图分类号
Q6 [生物物理学];
学科分类号
071011 ;
摘要
Treatment strategies for patients with severe aplastic anemia (SAA), depend on the severity of the disease, the age of the patient and the availability of a family donor. Progress in the past has included the early use of combined immunosuppressive therapy (IST) and better matching strategies to select unrelated donors. Currently, the actuarial 10-year survival in 2479 patients registered within the European Group for Blood and Marrow Transplantation (EBMT), is 73 and 68% for patients receiving. rst-line BMT or IST. T he outcome of BMT has significantly improved since 1996, and this is true for both matched sibling donor BMT as well as for alternative donor BMT. Survival is significantly better in children (<16 years) as compared with adults (79 vs 68%, P<0.0001). In contrast, there has been no significant improvement over time for patients receiving IST. A gain, results were significantly better in children compared with adults (81 versus 70%, P = 0.001), especially in very severe aplasia (83 versus 62%, P = 0.0002). This report outlines some of these results as a basis for treatment strategies in SAA.
引用
收藏
页码:S42 / S44
页数:3
相关论文
共 24 条
  • [1] ASCENSAO J, 1976, LANCET, V1, P669
  • [2] BACIGALUPO A, 1980, EXP HEMATOL, V8, P795
  • [3] Bacigalupo A, 2000, SEMIN HEMATOL, V37, P69, DOI 10.1016/S0037-1963(00)90031-3
  • [4] T-cell suppression mediated by mesenchymal stem cells is deficient in patients with severe aplastic anemia
    Bacigalupo, A
    Valle, M
    Podestà, M
    Pitto, A
    Zocchi, E
    De Flora, A
    Pozzi, S
    Luchetti, S
    Frassoni, F
    Van Lint, MT
    Piaggio, G
    [J]. EXPERIMENTAL HEMATOLOGY, 2005, 33 (07) : 819 - 827
  • [5] Fludarabine, cyclophosphamide and anti-thymocyte globulin for alternative donor transplants in acquired severe aplastic anemia:: a report from the EBMT-SAA Working Party
    Bacigalupo, A
    Locatelli, F
    Lanino, E
    Marsh, J
    Socié, G
    Maury, S
    Prete, A
    Locasciulli, A
    Cesaro, S
    Passweg, J
    [J]. BONE MARROW TRANSPLANTATION, 2005, 36 (11) : 947 - 950
  • [6] Antilymphocyte globulin, cyclosporine, prednisolone, and granulocyte colony-stimulating factor for severe aplastic anemia: an update of the GITMO/EBMT study on 100 patients
    Bacigalupo, A
    Bruno, B
    Saracco, P
    Di Bona, E
    Locasciulli, A
    Locatelli, F
    Gabbas, A
    Dufour, C
    Arcese, W
    Testi, G
    Broccia, G
    Carotenuto, M
    Coser, P
    Barbui, T
    Leoni, P
    Ferster, A
    [J]. BLOOD, 2000, 95 (06) : 1931 - 1934
  • [7] Marrow transplants from unrelated donors for patients with aplastic anemia: Minimum effective dose of total body irradiation
    Deeg, HJ
    Amylon, MD
    Harris, RE
    Collins, R
    Beatty, PG
    Feig, S
    Ramsay, N
    Territo, M
    Khan, SP
    Pamphilon, D
    Leis, JF
    Burdach, S
    Anasetti, C
    Hackman, R
    Storer, B
    Mueller, B
    [J]. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2001, 7 (04) : 208 - 215
  • [8] Rabbit antithymocyte globulin (r-ATG) plus cyclosporine and granulocyte colony stimulating factor is an effective treatment for aplastic anaemia patients unresponsive to a first course of intensive immunosuppressive therapy
    Di Bona, E
    Rodeghiero, E
    Bruno, B
    Gabbas, A
    Foa, P
    Locasciulli, A
    Rosanelli, C
    Camba, L
    Saracco, P
    Lippi, A
    Iori, AP
    Porta, F
    De Rossi, V
    Comotti, B
    Iacopino, P
    Dufour, C
    Bacigalupo, A
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 1999, 107 (02) : 330 - 334
  • [9] Addition of low-dose busulfan to cyclophosphamide in aplastic anemia patients prior to allogeneic bone marrow transplantation to reduce rejection
    Dulley, FL
    Vigorito, AC
    Aranha, FJP
    Sturaro, D
    Ruiz, MA
    Saboya, R
    Macedo, MCMA
    Da Silva, RL
    Chamone, DAF
    Mehta, J
    Bacigalupo, A
    De Souza, CA
    [J]. BONE MARROW TRANSPLANTATION, 2004, 33 (01) : 9 - 13
  • [10] Results and follow-up of a phase III randomized study of recombinant human-granulocyte stimulating factor as support for immunosuppressive therapy in patients with severe aplastic anaemia
    Gluckman, E
    Rokicka-Milewska, R
    Hann, I
    Nikiforakis, E
    Tavakoli, F
    Cohen-Scali, S
    Bacigalupo, A
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 2002, 119 (04) : 1075 - 1082